Enanta Pharmaceuticals | ENTA - Beban Penjualan Dan Administrasi

Harga Saham
12.51
Perubahan Harian
-0.49 -3.77%
Bulanan
-7.26%
Tahunan
98.26%
Q1 Perkiraan
12.13




Beban Penjualan Dan Administrasi Perubahan Tanggal
AbbVie USD 3.89B 325M 2025-12
Amgen USD 1.94B 237M 2025-12
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Immunic USD -0.24 0.03 2024-09
Incyte USD 390.41M 61.33M 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
J&J USD 6.75B 831M 2025-12
Karyopharm Therapeutics USD 27.19M 442K 2024-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
Merck USD 2.85B 215M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12